These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 426619)

  • 1. Dacarbazine and melphalan. Enhancement by dosage scheduling of the effect in combination treatment on the Harding-Passey melanoma in C3D2F1 mice.
    Hill HZ; Hill GJ; Szramowski J
    Arch Surg; 1979 Feb; 114(2):135-8. PubMed ID: 426619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
    Hill HZ; Hill GJ
    Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
    Hill HZ; Hill GJ; Miller CL; Pfaller M; Weiss K; Galin M
    Cancer Res; 1979 Mar; 39(3):934-9. PubMed ID: 427782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
    Dumont P; Atassi G; Tagnon HJ
    Eur J Cancer Clin Oncol; 1981 Sep; 17(9):1017-21. PubMed ID: 6895729
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 6. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 8. Scheduling of combination chemotherapy for a murine melanoma, with the subrenal capsular assay.
    Raina S; Hill HZ; Hill GJ; Rush BF
    J Surg Oncol; 1984 May; 26(1):51-2. PubMed ID: 6727385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G; Hafström L; Jönsson PE; Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of advanced malignant melanoma with DTIC].
    Jassem J; Kopacz A; Wojszwiłło-Geppert E
    Pol Tyg Lek; 1979 Feb; 34(8):293-5. PubMed ID: 441041
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chemotherapy of malignant melanoma using DTIC].
    Zaumseil RP; Fiedler H; Lübbe D
    Dermatol Monatsschr; 1977 Nov; 163(11):905-14. PubMed ID: 590586
    [No Abstract]   [Full Text] [Related]  

  • 12. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Carbone PP; Costello W
    Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
    Kleeberg UR; Schreml W
    Dtsch Med Wochenschr; 1976 Jun; 101(23):890-4. PubMed ID: 1269431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
    Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
    Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The combined action of 2,5,6-H3-DOPA and alkylating agents on Harding-Passy melanoma].
    Ivanov II; Vdovenko VM; Bobrova VN; Gavrilenko IS; Rumiantseva LN
    Vopr Onkol; 1972; 18(8):76-80. PubMed ID: 4657683
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
    Griswold DP; Dykes DJ; Kelley CA; Roberts BJ; Dominick CA
    Cancer Chemother Rep 2; 1974 Mar; 4(1):99-108. PubMed ID: 4524043
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination chemotherapy in disseminated melanoma and other solid tumors in adults.
    Gerner RE; Moore GE; Dickey C
    Oncology; 1975; 31(1):22-30. PubMed ID: 1099501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.